Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY
HKMPY Stock Chart & Stats
$42.02
$0.00(0.00%)
At close: 4:00 PM EST
$42.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$31.91 - $58.35
Previous CloseN/A
Volume13.00
Average Volume (3M)576.00
Market Cap
$3.69B
Enterprise Value$5.02B
Total Cash (Recent Filing)$354.00M
Total Debt (Recent Filing)$1.65B
Price to Earnings (P/E)11.5
Beta0.48
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.04%
Share Statistics
EPS (TTM)1.49
Shares Outstanding110,153,854
10 Day Avg. Volume104
30 Day Avg. Volume576
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)1.78
Price to Sales (P/S)1.38
P/FCF Ratio28.48
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue1.50
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda5.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelHikma's multi-segment model (injectables, generics, branded) and global distribution reduce single-market dependency and smooth revenue cycles. Over 2–6 months this structural diversification helps absorb regional reimbursement shifts and patent expiries while supporting cross-segment reinvestment.
RTU Injectables Pipeline And Market TractionA sizable RTU pipeline and early commercial traction for TYZAVAN represent durable, high-barrier product expansion in hospital sterile injectables. Capturing share in a large gram market supports sustainable revenue and margin improvement as RTU adoption and conversions increase over multiple years.
Strong Underlying Profitability And Rx RecoverySustained group EBITDA near 25% and a historically recovered Rx division imply resilient core economics. Even with near-term investments, higher structural EBITDA and a stable Rx profit base provide durable cash-earning potential and operational leverage as scale and CMO targets are realized.
Bears Say
Weak Cash ConversionEarnings quality is weakened by poor cash conversion: rising gap between net income and free cash flow limits capacity to self-fund capex, debt paydown or buybacks. Over the medium term this raises refinancing and flexibility risks if cash generation doesn't recover with margins.
Rising Leverage And Debt IncreaseMaterial debt increases and higher debt/equity reduce financial flexibility and elevate interest and covenant risk if operating cash flow weakens. This structural leverage makes the company more vulnerable to execution slippage or delayed cash recovery from investments and capacity projects.
Injectables Margin Reset And Delayed Capacity BenefitsA durable margin reset in injectables and pushed-out capacity/lauch timelines compress near-to-medium term profitability. Given injectables' importance, multi-year margin drag and late 2020s capacity inservice delays will postpone expected cash flow and CMO revenue upside for several years.
Hikma Pharmaceuticals News
HKMPY FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest stock price was $31.91 and its highest was $58.35 in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Hikma Pharmaceuticals PLC’s market cap is $3.69B.
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Aug 06, 2026 which is in 142 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Feb 26, 2026. The company reported $1.485 earnings per share for the quarter, beating the consensus estimate of N/A by $1.485.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Overvalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC pays a Semiannually dividend of $0.72 which represents an annual dividend yield of 4.04%. See more information on Hikma Pharmaceuticals PLC dividends here
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 110,153,854 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of $1.485 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -17.024%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in HKMPY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hikma Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.36%
12-Months-Change
Fundamentals
Return on Equity
15.83%
Trailing 12-Months
Asset Growth
10.48%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---